The estimated Net Worth of Bradley L Campbell is at least $17 Milión dollars as of 3 September 2024. Mr. Campbell owns over 7,500 units of Amicus Therapeutics Inc stock worth over $10,077,116 and over the last 17 years he sold FOLD stock worth over $2,808,342. In addition, he makes $4,141,140 as President, Chief Operating Officer a Director at Amicus Therapeutics Inc.
Bradley has made over 76 trades of the Amicus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of FOLD stock worth $64,575 on 3 September 2024.
The largest trade he's ever made was exercising 100,000 units of Amicus Therapeutics Inc stock on 3 January 2017 worth over $1,127,000. On average, Bradley trades about 9,053 units every 31 days since 2008. As of 3 September 2024 he still owns at least 894,154 units of Amicus Therapeutics Inc stock.
You can see the complete history of Mr. Campbell stock trades at the bottom of the page.
Bradley L. Campbell serves as President, Chief Operating Officer, Director of the Company. Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme© for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.
As the President, Chief Operating Officer a Director of Amicus Therapeutics Inc, the total compensation of Bradley Campbell at Amicus Therapeutics Inc is $4,141,140. There are 1 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Bradley Campbell is 44, he's been the President, Chief Operating Officer a Director of Amicus Therapeutics Inc since 2018. There are 19 older and 1 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Bradley's mailing address filed with the SEC is 47 HULFISH STREET, , PRINCETON, NJ, 08542.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris a Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: